ChemoFx assay (Precision Therapeutics Inc.) for prediction of response to chemotherapy for ovarian cancer
Record ID 32015000341
English
Authors' recommendations:
Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies. An estimated 21,980 new cases of ovarian cancer and 14,270 deaths from the disease are expected in the United States in 2014. In most cases, disease is widespread at the time of diagnosis. Estimated 5-year survival among patients with ovarian cancer is 44.6%; however, survival rates are much lower following early relapse. First-line treatment for ovarian cancer includes optimal debulking followed by multidrug chemotherapy with a platinum compound such as cisplatin or carboplatin and a taxane such as paclitaxel or docetaxel. The selection of chemotherapeutic agents is based on accumulated experience from clinical trials and treatment guidelines, but does not consider the sensitivity of the individual tumor to the agents selected. This generalized approach does not always lead to a partial or complete response, and patients with histologically similar tumors do not
necessarily respond similarly to treatments. For the majority of women with relapsed or recurrent disease, the choice of additional therapy depends on whether the tumor was sensitive or resistant to platinum compounds. To exploit the individual sensitivities of tumors, in vitro chemosensitivity testing has been developed to guide the selection of chemotherapeutic agents. In theory, selecting the most potent agents on the basis of chemosensitivity testing will lead to greater efficacy and overall survival (OS), and decrease toxicity from agents with limited efficacy. In practice, other factors affect responses to chemotherapy and ability to deliver treatment, such as concomitant medications, comorbidities, and blood supply to the tumor.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=9378
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antineoplastic Combined Chemotherapy Protocols
- Drug Screening Assays, Antitumor
- Neoplasm Recurrence, Local
- Neoplasm Staging
- Ovarian Neoplasms
- Survival Rate
- Drug-Related Side Effects and Adverse Reactions
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.